Recent studies have reported RP59500 (Synercid) (quinupristin-dalfopristin), a semisynthetic streptogramin, to have good in vitro activity against certain enterococcal strains, including vancomycin-resistant strains of Enterococcus faecium (3) (4) (5) . The purpose of the present study was to determine the in vitro activity of this new compound against a larger sample of resistant strains of enterococci and to compare its activity with those of several currently available antimicrobials.
detected in 46 (85.2%) E. faecalis isolates and 586 (59.2%) E. faecium isolates, with the MIC for 517 (81.8%) of these resistant strains being Ͼ2,000 g/ml.
Susceptibility to doxycycline was variable; we demonstrated nearly identical biphasic MIC distributions for the two species, with MICs for 723 (69.3%) isolates being Յ0.25 g/ml and the remainder of the susceptible strains clustering near the breakpoint (4 to 8 g/ml). Overall, 724 (73.1%) isolates of E. faecium and 40 (74.1%) isolates of E. faecalis were susceptible (MIC Յ 4 g/ml) to doxycycline.
The majority of strains tested (89.0%) were highly resistant to ciprofloxacin, with MICs being Ն32 g/ml. Only one strain of each species was susceptible (MIC Յ 1 g/ml), and 44 (4.4%) strains of E. faecium were intermediate (MIC ϭ 2 g/ml).
For chloramphenicol, 912 (92.1%) strains of E. faecium and 37 (68.5%) strains of E. faecalis were susceptible (MIC Յ 8 g/ml). However, the MIC for the large majority of these susceptible isolates for both species (882 of 949 [92.9%]) was at the breakpoint of 8 g/ml.
These in vitro results, if supported by clinical trials, would confirm the potential of RP59500 as a therapeutic agent in the treatment of E. faecium infections attributed to vancomycinresistant strains. However, its reported lack of bacteriocidal activity against such strains may limit its use in treatment of serious infections (2) (3) (4) (5) . 
